Companies Protagonist Therapeutics, Inc
Protagonist Therapeutics (PTG): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Protagonist Therapeutics, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers74th pct.Of 19 peer CEOs
CEO pay, last three years
- $7,067,572FY2023
- $9,473,819FY2024
- $12,871,506FY2025
CEO total pay was $12,871,506 in fiscal 2025, up from $9,473,819 in fiscal 2024.
FY2025: salary $715,500 · bonus $0 · stock awards $5,839,204 · option awards $5,618,010
Frequently asked questions
Who was the highest-paid executive at Protagonist Therapeutics, Inc in fiscal 2025?
As disclosed, Dinesh Patel (President and Chief Executive Officer) was the highest-paid executive at Protagonist Therapeutics, Inc in fiscal 2025, with total compensation of $12,871,506.
How does Protagonist Therapeutics, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Dinesh Patel's total compensation ranked at the 74th percentile of Protagonist Therapeutics, Inc's disclosed peer group.
What is Protagonist Therapeutics, Inc's CEO-to-median employee pay ratio?
As disclosed, Protagonist Therapeutics, Inc's CEO-to-median employee pay ratio was 30:1.
How much does Protagonist Therapeutics, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Protagonist Therapeutics, Inc reported total board compensation of $1,160,866 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dinesh Patel | $715,500 | $0 | $5,839,204 | $5,618,010 | $686,880 | $0 | $11,912 | $12,871,506 |
| President and Chief Executive Officer | ||||||||
| Arturo Molina | 572,000 | 0 | 1,601,610 | 1,543,628 | 366,080 | 0 | 11,912 | 4,095,230 |
| Chief Medical Officer | ||||||||
| Asif Ali | 500,000 | 0 | 1,238,745 | 1,192,502 | 320,000 | 0 | 6,242 | 3,257,489 |
| EVP, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dinesh Patel | $12,871,506 | $9,473,819 | $7,067,572 | ↑ +3,397,687 |
| Arturo Molina | 4,095,230 | 3,464,201 | — | ↑ +631,029 |
| Asif Ali | 3,257,489 | 2,810,873 | 1,402,215 | ↑ +446,616 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The executive compensation program focuses on attracting, retaining, and rewarding executive officers to promote long-term success by establishing internally equitable and competitive compensation levels. The program emphasizes pay-for-performance by tying a significant majority of compensation to short-term and long-term performance goals and aligning executive interests with stockholders through equity-based incentives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Asif Ali | OPTION | 2025-01-02 | — | — | 38,520 | — | $1,192,502 |
| Asif Ali | RSU | 2025-01-02 | — | — | 31,779 | — | 1,238,745 |
| Dinesh Patel | OPTION | 2025-01-02 | — | — | 181,472 | — | 5,618,010 |
| Dinesh Patel | RSU | 2025-01-02 | — | — | 149,800 | — | 5,839,204 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Asif Ali | $1,238,745 | $0 | $1,192,502 | 0.0% |
| Dinesh Patel | 5,839,204 | 0 | 5,618,010 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Asif Ali | RSU | 3,438 | — | $300,275 |
| Asif Ali | RSU | 3,542 | — | 309,358 |
| Asif Ali | Option | 6,875 | 19.19 | — |
| Dinesh Patel | Option | 7,813 | 28.73 | — |
| Asif Ali | RSU | 14,001 | — | 1,222,847 |
| Asif Ali | Option | 17,266 | 12.17 | — |
| Asif Ali | Option | 29,693 | 38.98 | — |
| Asif Ali | RSU | 31,779 | — | 2,775,578 |
| Asif Ali | Option | 40,625 | 23.42 | — |
| Dinesh Patel | RSU | 56,584 | — | 4,942,047 |
| Dinesh Patel | Option | 139,885 | 38.98 | — |
| Dinesh Patel | RSU | 149,800 | — | 13,083,532 |
| Dinesh Patel | Option | 162,500 | 12.17 | — |
| Dinesh Patel | Option | 164,193 | 23.42 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Sarah A. O’DowdIndependent · Audit · Nominating and Corporate Governance | $36,717 | $199,967 | $199,833 | — | $0 | $436,517 |
| Lewis T. Williams, M.D., Ph.DIndependent · Compensation | 32,016 | 199,967 | 199,833 | — | 0 | 431,816 |
| William D. WaddillIndependent · Audit (Chair) · Compensation | 32,016 | 199,967 | 199,833 | — | 0 | 431,816 |
| Bryan GiraudoIndependent · Audit · Nominating and Corporate Governance (Chair) | 32,016 | 199,967 | 199,833 | — | 0 | 431,816 |
| Harold E. Selick, Ph.DIndependent · Board Chair · Compensation (Chair) · Nominating and Corporate Governance | 28,266 | 199,967 | 199,833 | — | 0 | 428,066 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $161,031 |
| Equity awards (grant-date value) | $999,835 |
| All other compensation | $0 |
| Total cost of the board | $1,160,866 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Protagonist Therapeutics as a peer
Companies that benchmark against PTG
No companies currently name PTG as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AGIO Agios Pharmaceuticals, Inc.IDYA IDEAYA Biosciences, Inc.CRNX Crinetics Pharmaceuticals, Inc.AKRO Akero Therapeutics, Inc.IMVT Immunovant, Inc.ACLX Arcellx, Inc.KROS Keros Therapeutics, Inc.BHVN Biohaven, Ltd.KURA Kura Oncology, Inc.CLDX Celldex Therapeutics, Inc.NRIX Nurix Therapeutics, Inc.RYTM Rhythm Pharmaceuticals, Inc.CYTK Cytokinetics, Inc.GPCR Structure Therapeutics, Inc.DNLI Denali Therapeutics, Inc.SNDX Syndax Pharmaceuticals, Inc.IRON Disc Medicine, Inc.VKTX Viking Therapeutics, Inc.GERN Geron Corporation
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Therapeutics, Inc. | 2025 | Brian Lian | $672,000 | $17,756,817 | $2,468,016 | $373,000 | $21,269,833 |
| 2 | Immunovant, Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Arcellx, Inc. | 2025 | Rami Elghandour | 720,961 | 16,799,540 | 0 | 0 | 18,183,311 |
| 4 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 5 | Biohaven, Ltd. | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 6 | Protagonist Therapeutics, Inc | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 7 | Cytokinetics, Inc. | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 8 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 9 | Akero Therapeutics, Inc. | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 10 | Geron Corporation | 2025 | Harout Semerjian | 321,538 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 11 | Disc Medicine, Inc. | 2025 | John Quisel | 695,000 | 4,285,817 | 4,441,046 | 554,263 | 9,986,626 |
| 12 | Ideaya Biosciences, Inc. | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 13 | Structure Therapeutics, Inc. | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 14 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 15 | Nurix Therapeutics, Inc. | 2025 | Arthur Sands | 674,584 | 0 | 5,166,196 | 510,000 | 6,374,138 |
| 16 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 17 | Celldex Therapeutics, Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 18 | Denali Therapeutics, Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 19 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 20 | Keros Therapeutics, Inc. | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc | not disclosed | Option 50 · RSU 50 | not disclosed | Aon |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Akero Therapeutics, Inc. | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arcellx, Inc. | not disclosed | RSU 100 | not disclosed | Meridian Compensation Partners, LLC |
| Biohaven, Ltd. | not disclosed | not disclosed | not disclosed | Aon |
| Celldex Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Cytokinetics, Inc. | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Denali Therapeutics, Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Disc Medicine, Inc. | 145% | RSU 50 · Options 50 | not disclosed | Pearl Meyer |
| Geron Corporation | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| Ideaya Biosciences, Inc. | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Keros Therapeutics, Inc. | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Nurix Therapeutics, Inc. | not disclosed | Option 60 · RSU 40 | not disclosed | Aon plc |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Structure Therapeutics, Inc. | 125% | Options 67 · RSU 33 | No | Aon |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Viking Therapeutics, Inc. | not disclosed | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 30 : 1 |
|---|---|
| CEO total compensation | $12,871,506 |
| Median employee compensation | $428,422 |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (36 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Dinesh Patel. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE” · page 47. As printed: 12,871,506. View filing ↗
- Section 01, Arturo Molina. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE” · page 47. As printed: 4,095,230. View filing ↗
- Section 01, Asif Ali. DEF 14A, filed 2026-04-28. Section “2025 SUMMARY COMPENSATION TABLE” · page 47. As printed: 3,257,489. View filing ↗
- Section 03, Asif Ali OPTION. DEF 14A, filed 2026-04-28. Section “2025 GRANTS OF PLAN-BASED AWARDS TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Asif Ali RSU. DEF 14A, filed 2026-04-28. Section “2025 GRANTS OF PLAN-BASED AWARDS TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Dinesh Patel OPTION. DEF 14A, filed 2026-04-28. Section “2025 GRANTS OF PLAN-BASED AWARDS TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Dinesh Patel RSU. DEF 14A, filed 2026-04-28. Section “2025 GRANTS OF PLAN-BASED AWARDS TABLE” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 30 : 1. View filing ↗
- Section 08, Sarah A. O’Dowd. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 436,517. View filing ↗
- Section 08, Lewis T. Williams, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 431,816. View filing ↗
- Section 08, William D. Waddill. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 431,816. View filing ↗
- Section 08, Bryan Giraudo. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 431,816. View filing ↗
- Section 08, Harold E. Selick, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 428,066. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 161,031 + equity 999,835 + all other 0 = 1,160,866, summed across the director compensation table rows.
- Viking Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Viking Therapeutics, Inc.'s own proxy. As printed: 21,269,833. View filing ↗
- Immunovant, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. View filing ↗
- Arcellx, Inc., Section 10b CEO total. 10-K/A, filed 2026-04-24. CEO total compensation as printed in Arcellx, Inc.'s own proxy. As printed: 18,183,311. View filing ↗
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- Biohaven, Ltd., Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven, Ltd.'s own proxy. As printed: 13,500,438. View filing ↗
- Protagonist Therapeutics, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics, Inc's own proxy. As printed: 12,871,506. View filing ↗
- Cytokinetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics, Inc.'s own proxy. As printed: 11,881,456. View filing ↗
- Crinetics Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. View filing ↗
- Akero Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero Therapeutics, Inc.'s own proxy. As printed: 10,465,855. View filing ↗
- Geron Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. View filing ↗
- Disc Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Disc Medicine, Inc.'s own proxy. As printed: 9,986,626. View filing ↗
- Ideaya Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences, Inc.'s own proxy. As printed: 9,512,640. View filing ↗
- Structure Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Structure Therapeutics, Inc.'s own proxy. As printed: 8,429,887. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Nurix Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Nurix Therapeutics, Inc.'s own proxy. As printed: 6,374,138. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Celldex Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. View filing ↗
- Denali Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics, Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Kura Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. View filing ↗
- Keros Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics, Inc.'s own proxy. As printed: 2,540,204. View filing ↗